ASAHI KASEI/ JP3111200006 /
| 12/4/2023 8:10:46 AM | Chg. +0.0140 | Volume | Bid12:43:43 PM | Ask12:43:43 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 6.1620EUR | +0.23% | 0 Turnover: 0.0000 |
6.1640Bid Size: 828 | 6.4720Ask Size: 789 | 8.65 bill.EUR | - | - |
GlobeNewswire
2/17/2022
OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Tra...
GlobeNewswire
2/15/2022
Basilea to become a leading anti-infectives company backed by strong financial results 2021
GlobeNewswire
1/31/2022
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obt...
GlobeNewswire
12/16/2021
Sustainable Prefabricated Custom Home Builder to Expand Operations to Tejon Ranch
GlobeNewswire
9/30/2021
Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of i...
GlobeNewswire
9/8/2021
Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategi...
GlobeNewswire
8/17/2021
Basilea reports strong financial results for half-year 2021 with significantly increased cash flow f...
GlobeNewswire
7/26/2021
Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavucon...
GlobeNewswire
5/28/2021
DENSO Announces Recipients of 2020 North America Business Partner of the Year Awards
GlobeNewswire
5/27/2021
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
GlobeNewswire
5/27/2021
Jeito Capital leads oversubscribed $92 million Series C financing round in Pulmocide
GlobeNewswire
5/27/2021
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
GlobeNewswire
4/26/2021
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, M...
GlobeNewswire
3/16/2021
Rapid Micro Biosystems Raises $81M to Continue Global Expansion of Automated Pharmaceutical QC Platf...
GlobeNewswire
2/16/2021
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of i...
GlobeNewswire
1/7/2021
Basilea’s partner Asahi Kasei Pharma completes patient enrolment in phase 3 study with antifungal is...